GSK won FDA approval for Jideytro (zidesamtinib), moving rapidly from deal close to commercialization after acquiring Nuvalent for $10.6 billion last week. The approval covers adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who previously received a ROS1 kinase inhibitor. Regulators cleared the therapy ahead of the September 18 deadline, reflecting prior breakthrough therapy and orphan drug designations. The approval also starts GSK’s return on an oncology push that includes other recent acquisitions and partner-led programs.